Press releases
- Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
- Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
- Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
- Sage Therapeutics to Present at Upcoming March Investor Conferences
- Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
More ▼
Key statistics
On Friday, SAGE Therapeutics Inc (SG7:BRN) closed at 20.74, 0.00% below its 52-week high of 20.74, set on Feb 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 20.74 |
---|---|
High | 20.74 |
Low | 20.74 |
Bid | 20.36 |
Offer | 20.58 |
Previous close | 20.74 |
Average volume | -- |
---|---|
Shares outstanding | 60.18m |
Free float | 52.68m |
P/E (TTM) | -- |
Market cap | 788.69m USD |
EPS (TTM) | -8.40 USD |
Data delayed at least 15 minutes, as of Feb 09 2024.
More ▼